HIV and hepatitis B co-infection in Africa

The Lancet Infectious Diseases

Volumn 8, Issue 4, 2008, Pages 210-211

  Lessells, Richard J ^a,c   Main, Janice ^b   Cooke, Graham S ^b,c  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; VIRUS DNA; ZIDOVUDINE;

AFRICA; ANTIBIOTIC RESISTANCE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DISEASE MARKER; DRUG SUBSTITUTION; DRUG TOLERABILITY; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MIXED INFECTION; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SURVIVAL; VIRUS DETECTION; VIRUS MUTATION; VIRUS REPLICATION;

AFRICA; HEPATITIS B; HIV INFECTIONS; HUMANS;

EID: 40749092432     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(08)70047-1     Document Type: Letter

References (11)

1. Hoffman C., and Thio C. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 7 (2007) 402-409
2. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public-health approach. 2006 revision. http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf (accessed Feb 19, 2008).
3. Mphahlele M., Lukhwareni A., Burnett R., Moropeng L., and Ngobeni J. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 35 (2006) 14-20
4. Nelson M, Bhagani S, Fisher M, et al. A 48-week study of tenofovir or lamivudine or a combination of tenofovir and lamivudine for the treatment of chronic hepatitis B in HIV/HBV-co-infected individuals. 13th Conference on Retroviruses and Opportunistic Infections; Denver, CO, USA; Feb 5-8, 2006. Abstract 831.
5. Medical Research Council Clinical Trials Unit. Development of antiretroviral therapy in Africa. http://www.ctu.mrc.ac.uk/dart/summary.asp (accessed Feb 19, 2008).
6. Bessesen M., Ives D., Condreay L., Lawrence S., and Sherman K. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 28 (1999) 1032-1035
7. Burnett R., Francois G., Kew M., et al. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int 25 (2005) 201-213
8. Matthews G., Bartholomeusz A., Locarnini S., et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 20 (2006) 863-870
9. Ramos B., Nunez M., Martin-Carbonero L., et al. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 44 (2007) 557-561
10. Santos E., Sucupira M., Arabe J., and Gomes S. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine. BMC Infect Dis 4 (2004) 29
11. Coleman P. Detecting hepatitis B surface antigen mutants. Emerg Infect Dis 12 (2006) 198-203